Search results

563 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Clinical guidelines Remove Clinical guidelines filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Antimicrobial prescribing guidelines Remove Antimicrobial prescribing guidelines filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter

Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]

In development [GID-TA10770] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

In development [GID-TA10587] Expected publication date: 02 June 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]

In development [GID-TA10643] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]

In development [GID-TA10639] Expected publication date: 09 March 2022

Type

Technology appraisal guidance

Status

In development
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Short bowel syndrome - teduglutide [ID885]

In development [GID-TA10048] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer [ID3929]

In development [GID-TA10825] Expected publication date: 30 March 2022

Type

Technology appraisal guidance

Status

In development
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]

In development [GID-TA10373] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Multiple sclerosis in adults: management

In development [GID-NG10153] Expected publication date: 20 July 2022

Type

NICE guideline

Status

In development
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]

In development [GID-TA10544] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Antenatal care

In development [GID-NG10096] Expected publication date: 11 August 2021

Type

NICE guideline

Status

In development
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]

In development [GID-TA10632] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]

In development [GID-TA10427] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]

In development [GID-TA10636] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bulevirtide for treating chronic hepatitis D [ID3732]

In development [GID-TA10652] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]

In development [GID-TA10739] Expected publication date: 25 May 2022

Type

Technology appraisal guidance

Status

In development
Ibrutinib for treating Waldenstrom's macroglobulinaemia (CDF Review of TA491) [ID3778]

In development [GID-TA10827] Expected publication date: 14 December 2021

Type

Technology appraisal guidance

Status

In development
Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [ID1602]

In development [GID-TA10524] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]

In development [GID-TA10584] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atherothrombotic events - vorapaxar [ID616]

In development [GID-TAG493] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Head and neck cancer - intensity modulated radiotherapy [ID15]

In development [GID-TAG397] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Glaucoma - lerdelimumab (CAT-152) [ID383]

In development [GID-TAG381] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610

In development [GID-TA10499] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]

In development [GID-TA10416] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
OTL-200 for treating metachromatic leukodystrophy [ID1666]

In development [GID-HST10028] Expected publication date: 13 August 2021

Type

Highly specialised technologies guidance

Status

In development
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]

In development [GID-TA10484] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Baloxavir marboxil for treating influenza [ID1537]

In development [GID-TA10559] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]

In development [GID-TA10491] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: 17 November 2021

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]

In development [GID-TA10693] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]

In development [GID-TA10692] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lifitegrast for treating dry eye disease [ID1229]

In development [GID-TA10196] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abicipar pegol for treating wet age-related macular degeneration ID1533

In development [GID-TA10511] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Melanoma (metastatic) - talimogene laherparepvec [ID508]

In development [GID-TAG509] Expected publication date: 28 September 2016

Type

Technology appraisal guidance

Status

In development
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]

In development [GID-TA10026] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Psoriasis - briakinumab (suspended) [ID65]

In development [GID-TAG412] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoarthritis - naproxcinod [ID417]

In development [GID-TAG426] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]

In development [GID-TAG418] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

In development [GID-TAG456] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (acute lymphoblastic) - dasatinib [ID386]

In development [GID-TAG399] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]

In development [GID-TAG398] Expected publication date: 01 January 2011

Type

Technology appraisal guidance

Status

In development
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

In development [GID-TAG414] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Diabetic foot ulcers - new treatments [ID381]

In development [GID-TAG371] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous leg ulcers - new treatments [ID394]

In development [GID-TAG370] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Venous thromboembolism (VTE) - ximelagatran [ID396]

In development [GID-TAG378] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]

In development [GID-TA10690] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

In development [GID-TA10507] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Type 2 diabetes in adults: management (update)

In development [GID-NG10160] Expected publication date: TBC

Type

NICE guideline

Status

In development